COMPANY PROFILE · UPDATED 01 AUG 2026

4D Molecular Therapeutics

4d Molecular Therapeutics, LLC operates as a biotechnology company. The Company designs, develops, and commercializes transformative gene therapeutic products for unmet medical conditions. 4d Molecular Therapeutics serves customers in the…

Emeryville, CA

4dmoleculartherapeutics.com ↗

Work at 4D Molecular Therapeutics? Claim this profile

Healthcare & Biotech Biotech & Drug Discovery Medical Organizations Health Care Companies Software Companies In Emeryville Tech Companies In The East Bay Area Has Woman Founder Biotechnology CompaniesPost Ipo Equity

This is the record ChatGPT, Claude and Google read about 4D Molecular Therapeutics. Claiming it controls the source; answers update as assistants re-crawl.

Founded: 2013
Headcount: 160
Open roles: 18
Last raised: Post Ipo Equity

LOCATIONS

Where they work

4D Molecular Therapeutics offices

Emeryville, CA5858 Horton Street #455

FUNDING

Capital raised

Total raised

$702,499,995

Investors

Amzak Health Investors ArrowMark Colorado Holdings BVF Partners Berkeley Catalyst Fund Casdin Capital Chiesi Ventures CureDuchenne Ventures Cystic Fibrosis Foundation Janus Capital Longevity Vision Fund Mirae Asset Octagon Capital Advisors Pappas Capital Perceptive Advisors Pfizer Venture Investments QUAD Investment Management Ridgeback Capital Management Viking Global Investors

Funding rounds

Post Ipo Equity
Cystic Fibrosis Foundation
$100MNov 6, 2025
Post Ipo Equity
Cystic Fibrosis Foundation
$7.5MOct 13, 2025
Post Ipo Equity
$300MFeb 5, 2024
Post Ipo Equity
$120MMay 3, 2023
Series C
Viking Global Investors, Cystic Fibrosis Foundation, Ridgeback Capital Management, Amzak Health Investors, ArrowMark Colorado Holdings, Casdin Capital, Perceptive Advisors, Berkeley Catalyst Fund, Pfizer Venture Investments, QUAD Investment Management, Chiesi Ventures, Pappas Capital, BVF Partners, Mirae Asset, Longevity Vision Fund, Octagon Capital Advisors
$75MJun 15, 2020
IPO
UndisclosedJan 1, 2020
Series B
Viking Global Investors, CureDuchenne Ventures, Ridgeback Capital Management, Mirae Asset, Perceptive Advisors, ArrowMark Colorado Holdings, Janus Capital, Pappas Capital, Pfizer Venture Investments, Berkeley Catalyst Fund, Chiesi Ventures, BVF Partners
$90MSep 4, 2018
Series Unknown
Cystic Fibrosis Foundation
$3MSep 18, 2017
Series Unknown
$7MAug 12, 2015

Funding data via Diffbot, SEC EDGAR filings and company announcements — a round from a filing or announcement links to it

TECH STACK

How 4D Molecular Therapeutics builds

Extracted from 4D Molecular Therapeutics’s job postings we’ve tracked

×N is how many of 4D Molecular Therapeutics’s open roles mention that technology.

Other Software & Platforms

Microsoft Office×3 NetSuite×3 Veeva Vault×3 Greenhouse Microsoft Project

Cloud Platforms

Google Cloud×9 Microsoft Azure

Analytics & BI

Microsoft Excel×2

CRM & Sales Tools

Veeva CRM×2

Collaboration & Productivity

Smartsheet

Databases

SQL

Stack wrong or out of date? Claim 4D Molecular Therapeutics to correct it

OPEN ROLES

Hiring at 4D Molecular Therapeutics

View all 18 open roles →

Hiring team? Claim the profile to keep roles and the careers link accurate

LEADERSHIP

Founders & key people

David Kirn

CEO at 4D Molecular Therapeutics

4D Molecular TherapeuticsIGNITE ImmunotherapyUniversity of California BerkeleyJohnson & JohnsonCelgeneJennerexUniversity of California BerkeleyHaas School of Business - UC BerkeleyUCSFHarvard Medical School

Theresa Janke

Management at 4D Molecular Therapeutics

4D Molecular TherapeuticsIGNITE ImmunotherapySillaJenCelgeneJennerex Biotherapeutics UlcAbbott VascularUniversity of California Santa Barbara

David Schaffer

Researcher ORCID ID = 0000-0002-9625-0121

QB3ValitorUniversity of California BerkeleyAxent BiosciencesGenEditBakar LabsMassachusetts Institute of Technology (MIT)Stanford UniversityRidge High School

SIMILAR COMPANIES